Jim Cramer
Cramer: Costco not carried out 'saturating the earth' as new China retailer lures significant crowds
Wholesale retailer Costco has a high-high quality issue on its palms, CNBC’s Jim Cramer mentioned Friday in reaction to the “purchasing frenzy” at its new China retail outlet. Bloomberg described that tens of countless numbers of people lined up outside the house of Costco’s most up-to-date store in the southern Chinese town of Shenzhen for […]
Read More
Walgreens and 3 other health-care stocks are going into our Bullpen watch list
We’re making our first Bullpen update of 2024. The Bullpen is a collection of stocks identified by the CNBC Investing Club team as having the potential to join Jim Cramer’s Charitable Trust. We’re highlighting the four most interesting investment opportunities we found out of the handful of company CEOs Jim interviewed at this week’s JPMorgan […]
Read More
Cramer's 7 days in advance: Earnings year kicks off following JPMorgan Health care Convention
CNBC’s Jim Cramer on Friday instructed traders what to observe for on Wall Street next 7 days, highlighting JPMorgan‘s industry-shifting health-care meeting in San Francisco. Getting location from Monday to Thursday, the meeting is a single of the year’s most significant gatherings of key industry CEOs where they expose earnings assistance and updates on clinical […]
Read More
Obesity and Alzheimer's drugs pack one-two punch to power Eli Lilly higher in 2024
Investor optimism for Eli Lilly ‘s diabetes and obesity treatments in 2023 lifted the stock to its seventh annual gain in a row. In the new year, it should be the same old story. Shares of Eli Lilly have taken a breather over the past three months, as investors book profits in the top performer […]
Read More
Here’s a rapid-fire update on all 33 stocks in our portfolio, including those Cramer would buy on dips
Jim Cramer ran through all 33 stocks in his Charitable Trust portfolio during the December edition of the CNBC Investing Club’s Monthly Meeting. Source
Read More
Prescriptions for Eli Lilly’s new weight-loss drug get off to a strong start and confirm bright outlook
The launch of Eli Lilly ‘s weight-loss drug Zepbound — a key pillar of our investment thesis in the pharmaceuticals giant — is going swimmingly in the U.S., Jefferies said Friday. Weekly Zepbound prescriptions totaled 7,700 in the week ended Dec. 8, its fourth on the U.S. market, according to Jefferies, which cited data compiled […]
Read More
Weight gain after stopping Eli Lilly's new obesity treatment should help, not hurt the stock
Some Eli Lilly investors appear concerned about clinical trial data that showed patients regained weight after they stopped taking the company’s obesity drug Zepbound. The situation seems rather clear-cut to us: It’s no reason to sell. Eli Lilly shares on Tuesday shook off afternoon losses to close higher by 0.12%, at $584.76 each — a […]
Read More
Flying solo without Cigna will keep Humana focused on 2 big priorities in the year ahead
It looks like Cigna has scrapped its takeover bid for Club holding Humana , removing a dark cloud over both stocks that’s lingered since the acquisition talks surfaced nearly two weeks ago. Cigna and Humana were unable to agree on an acquisition price and other financial terms, The Wall Street Journal reported Sunday. Cigna will […]
Read More
Signet Jewelers CEO states the ɾngagement trough' induced by Covid has passed, relationship proposals are coming again
Signet Jewelers CEO Gina Drosos told CNBC’s Jim Cramer on Tuesday that marriage proposals are eventually on the rise, decades after Covid disrupted regular dating designs and harm the company’s business. “We know a ton about courting couples, and so we experience very confident that our predictions are right, and that the engagement trough has […]
Read More
Signs of a sector rotation — additionally 2 more themes to enjoy in the inventory current market
It was an additional gain for the bulls this 7 days. Wall Avenue commenced the month of December greater Friday — creating on November’s rally, which broke a three-thirty day period losing streak. November genuinely lived up to its stellar popularity, with monthly gains of almost 8.8% for the Dow , about 8.9% for the […]
Read More